<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608266</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200702</org_study_id>
    <nct_id>NCT04608266</nct_id>
  </id_info>
  <brief_title>CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients</brief_title>
  <acronym>CAMOVID</acronym>
  <official_title>A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine the therapeutic effect and tolerance of&#xD;
      Camostat mesylate, compared to placebo in adult patients with ambulatory COVID-19 disease,&#xD;
      presenting with risk factors of severe COVID-19. Camostat mesylate is a serine protease&#xD;
      TMPRSS2 (Transmembrane Serine Protease 2) inhibitor which has been successfully and safely&#xD;
      used to treat pancreatitis-associated pain and post-operative reflux oesophagitis in Japan.&#xD;
      More recently, it has been shown to inhibit SARS-CoV-2 viral entry and reduce infection of&#xD;
      human primary pneumocytes and lung cell lines.&#xD;
&#xD;
      Camostat mesylate or placebo will be administered to consenting adult patients with&#xD;
      virologically confirmed COVID-19, not requiring initial hospitalization. All patients will&#xD;
      receive standard of care along with randomized treatments. Outcomes of included patients will&#xD;
      be compared between the 2 groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization for COVID-19 deterioration or death without hospitalization</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients hospitalized for COVID-19 deterioration or who died without hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of patients with at least one adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of patients with at least one serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigational medication discontinuation</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of patients who discontinued the investigational medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for COVID-19 deterioration or death without hospitalization, evaluated by independent adjudication comittee</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients hospitalized for COVID-19 deterioration (reviewed by independent adjudication comitter) or who died without hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement using the Word Health Organization (WHO) COVID-19 scale</measure>
    <time_frame>Day 7, 14, 21</time_frame>
    <description>WHO clinical scale: Uninfected - No clinical or virological evidence of infection: 0; Ambulatory - No limitation of activities: 1; Ambulatory - limitation of activities: 2; Hospitalized - no oxygen therapy: 3; Hospitalized - oxygen by mask or nasal prongs: 4; Hospitalized; oxygen by non invasive ventilation or High flow: 5; Intubation and Mechanical ventilation: 6; Mechanical ventilation + additional organ support (pressors, Renal replacement therapy, ECMO):7; Dead: 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intensive care</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients admitted to an intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of days alive without hospitalization up to day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for invasive mechanical ventilation for severe COVID-19</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients with initiation of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for oxygen therapy for COVID-19</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients with initiation of oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 90</time_frame>
    <description>Proportion of patients alive at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of days alive without symptoms at day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 virological assessment</measure>
    <time_frame>Day 7, 14, 21</time_frame>
    <description>By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) on nasal swab and droplet quantification of SARS-CoV2 ribonucleic acid-emia (RNAemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 serological assessment</measure>
    <time_frame>Day 7, 14, 21 and 90</time_frame>
    <description>SARS-CoV2 antibodies quantification in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood lymphocyte phenotyping</measure>
    <time_frame>Day 1, 14, 90</time_frame>
    <description>Peripheral blood lymphocyte phenotyping with telomere length measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney failure</measure>
    <time_frame>Day 21</time_frame>
    <description>Acute kidney failure defined as at least serum creatinine increase of 0.3mg/dl or 1.5-1.9 times baseline and/or oliguria &lt; 0.5ml/kg/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <description>estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urea in blood</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <description>Uricemia in mmol/L or mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of potassium in blood</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <description>Kaliemia in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <description>Liver transaminases dosage on blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function (2)</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <description>Gamma-glutamyl transferase (gamma-GT) dosage on blood sample</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biobanking for biomarker assessment</measure>
    <time_frame>Day 1, 7, 14, 21, 90</time_frame>
    <description>Biobanking of blood samples for predictive biomarker assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">596</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Camostat mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camostat mesylate, oral administration 600mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat Mesylate</intervention_name>
    <description>Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days</description>
    <arm_group_label>Camostat mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, oral administration 2 tablets every 8 hours for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old&#xD;
&#xD;
          -  Patients with an increased risk of severe COVID-19 belonging to one or more of the&#xD;
             following groups :&#xD;
&#xD;
               -  Age ≥ 50 years&#xD;
&#xD;
               -  Body Mass Index ≥ 30 kg/m²&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Chronic renal failure (eGFR &lt;60 mL/min)&#xD;
&#xD;
               -  Chronic heart disease&#xD;
&#xD;
               -  Asthma/Chronic Obstructive Pumonary Disease/Cystic fibrosis&#xD;
&#xD;
               -  Chronic liver disease&#xD;
&#xD;
               -  Chronic neurological disease&#xD;
&#xD;
               -  Solid organ transplant&#xD;
&#xD;
               -  Bone marrow transplant&#xD;
&#xD;
               -  Sickle cell anemia/ Major thalassemias&#xD;
&#xD;
               -  Active or currently treated or &lt;1 year diagnosed cancer&#xD;
&#xD;
               -  Active or currently treated or &lt;1 year diagnosed malignant blood disease&#xD;
&#xD;
               -  Immunosuppressive treatment observed for more than 1 month&#xD;
&#xD;
          -  Laboratory confirmed SARS-CoV2 infection with mild COVID-19, fulfilling all the&#xD;
             following criteria:&#xD;
&#xD;
               -  Positive SARS-CoV-2 RT-PCR nasal swab samples AND&#xD;
&#xD;
               -  Clinical symptoms and signs consistent with SARS-CoV2 infection including but not&#xD;
                  limited to, fever, upper respiratory tract infection signs, digestive signs,&#xD;
                  muscle pain, anosmia, dysgueusia…(1)&#xD;
&#xD;
          -  Informed consent to participate to the trial&#xD;
&#xD;
          -  Patients must be able and willing to comply with study visits and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initial need for hospitalization for COVID-19 management&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Participation to another interventional drug trial&#xD;
&#xD;
          -  Subject protected by law under guardianship or curatorship&#xD;
&#xD;
          -  Absence of health insurance&#xD;
&#xD;
          -  Known hypersensitivity to camostat mesylate&#xD;
&#xD;
          -  Known person sharing the same household already included in the study&#xD;
&#xD;
          -  Participation to another COVID-19 ambulatory interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Boutboul, MD PhD</last_name>
    <phone>+33 1 42 49 91 40</phone>
    <email>david.boutboul@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaëtan Plantefève, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël Lepeule, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Kassasseya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Constance Guillaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Bartolucci, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorothée Vallois, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Boutboul, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Peyrony, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Santé Richerand</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariela Skendi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

